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Abstract
Pregnancy associated plasma protein-A (PAPP-A) plays an important role in the
activity of the Insulin-like Growth Factor (IGF) family by proteolytically cleaving IGFBinding Protein-4 (IGFBP-4) causing it to dissociate from IGF-I in vivo. This increases
the bioavailability of IGF-I, allowing IGF-I to participate in growth and development.
My goal was to evaluate the ability of PAPP-A to directly stimulate proliferation and
differentiation of human adult mesenchymal stem cells (hAMSC) cells in vitro.
Commercially available PAPP-A, comprised of a heterotetrameric complex
consisting of two PAPP-A subunits and two pro-MBP (proform of eosinophil major basic
protein) subunits, was used in the following studies. Proliferation of hAMSC in response
to PAPP-A was evaluated via CyQUANT and BrdU incorporation. Cells were arrested at
G0 prior to treatment with 200 ng/mL PAPP-A. CyQUANT and BrdU incorporation
results did not show statistically significant evidence of proliferation of hAMSC when
treated with PAPP-A.
To test for differentiation, hAMSC were treated with mesenchymal stem cell
growth medium – MSCGM (negative control), an osteogenic supplement (positive
control) or 200 ng/mL PAPP-A in MSCGM for multiple time points. hAMSC were
harvested for RNA extraction followed by qPCR analysis to detect osteoblastic
differentiation via multiple marker genes. qPCR results showed a statistically significant
increase in Runx2 and alkaline phosphatase gene expression in hAMSC when treated
with PAPP-A for 12 and 18 hours respectively.
My results indicate that addition of PAPP-A to cell culture medium does not
affect proliferation of hAMSC. However, treatment with PAPP-A for 12 and 18 hours
viii

increases Runx2 and alkaline phosphatase gene expression respectively in hAMSC
suggesting that PAPP-A plays a role in osteoblast differentiation in an in vitro
environment. Further elucidation of this role is necessary to determine PAPP-A’s
involvement in osteoblast development and its potential therapeutic role in bone
degenerative diseases such as osteoporosis.
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CHAPTER 1- INTRODUCTION AND OBJECTIVES

1.1 Introduction
Bone degenerative diseases are characterized by a decrease in bone mineral density or
bone strength, bone fractures and a loss of bone mass. These characteristics are due either to an
excess of bone resorption or a decrease in bone formation. Osteoporosis and Paget’s disease of
bone are both caused by excess bone resorption and together they affect 18.2 million people a
year in the United States [1-3]. The understanding of bone biology through the use of molecular
techniques, transgenic and knockout mice and identification of mutated genes has aided in the
development of drugs used to treat these skeletal diseases.
Numerous studies of growth factors that affect the development, activation, and
regulation of bone cells have been conducted. There are three major families of growth factors
that are non-specific to cells of the osteoblast lineage but are key local regulators of
osteogenesis: bone morphogenic proteins (BMPs), transforming growth factor betas (TGF-βs)
and insulin-like growth factors (IGFs). BMPs play a role in precursor cell replication and
osteoblast commitment. TGF-βs affect committed bone cell replication and osteoblast matrix
production. IGFs broaden and integrate the effects of both factors [4]. Key players involved in
the pathway include IGF-I, Insulin-like growth factor binding protein-4 (IGFBP-4) and a novel
component: Pregnancy associated plasma protein A (PAPP-A). Studying the regulation and
interaction of these components has the potential to yield therapeutic agents useful for treatment
of skeletal diseases.
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1.2 Bone Biology
1.2.1 Bone Composition and Formation
The bones in our bodies are organized into two primary groups: the axial skeleton and the
appendicular skeleton. The axial skeleton is composed of flat bones such as the vertebrae,
pelvis, sternum and skull. The appendicular skeleton consists of long bones. The long bones of
the appendicular skeleton are further divided into three parts: the epiphysis, metaphysis and
diaphysis. The epiphysis is the portion of bone that is found at either end and is separated from
the rest of the bone by a layer of growth cartilage called the physis. The metaphysis is located
between the physis and the central portion of the long bone shaft, known as the diaphysis. The
metaphysis is the region where bone remodeling occurs. The diaphysis encompasses the
majority of the length of the bone [5].
There are two basic types of bone tissue that make up the skeletal system: cortical and
cancellous bone. Cortical bone, which is also known as compact or dense bone, makes up
approximately 80% of the skeletal mass, weighing four times as much as cancellous bone. It
makes up the shafts of long bones in the appendicular skeleton as well as the outer envelopes of
all bones. Cortical bone tends to be in a solid, cylindrical form and is subject to bending and
torsional forces as well as compressive loads. Ultimately, cortical bone serves protective,
supportive and mechanical functions for the skeleton. The second type of bone tissue, cancellous
bone, is also known as trabecular or spongy bone. It makes up the inner parts of the bones of
vertebrae and the pelvis as well as the ends of long bones in the axial skeleton. The structure of
cancellous bone resembles a lacy or honeycombed configuration making it ideal for housing
bone forming cells and serving as a reservoir for minerals. In this bone type, the turnover rate is
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much higher due to its greater surface area as well as its reservoir of minerals and bone forming
cells. Cancellous bone is best suited for resisting compressive loads due to its structure [5-7].
Additionally, bone tissue can be classified according to its matrix arrangement: woven
bone and lamellar bone. Cancellous and cortical bone can consist of either woven or lamellar
bone [7]. Woven bone is considered to be an immature version with collagen fibers found in
irregular random arrays. It can be found in embryos, newborns, in certain metaphyseal regions
of growing bone and in fracture calluses. In addition, woven bone can be found in bone tumors
such as osteogenesis imperfecta and in individuals with Paget’s disease of bone. Lamellar bone
on the other hand, is a more mature version resulting from the remodeling of woven bone or
preexisting bone tissue and contains highly organized collagen fibers [5].
On a microscopic level, bones are composed of two main phases: an organic phase and an
inorganic phase. Approximately 70% of the weight of bone is composed of the inorganic or
mineral phase, 5-8% is water and the remaining amount is the organic phase or extracellular
matrix. Roughly 95% of the inorganic phase is composed of a calcium phosphate mineral
analogous to crystalline hydroxyapatite. The other 5% of the inorganic phase consists of
impurities located within the calcium phosphate mineral. The organic phase is composed
primarily of type I collagen and a variety of noncollagenous proteins. A small portion of the
organic phase is composed of cells to be discussed later [5, 6].

1.2.2 Bone Cells and the extracellular matrix
The organic phase of bone tissue is composed of approximately 98% type I collagen and
2% cells and noncollagenous proteins. The organic phase of bone is commonly referred to as the
extracellular matrix and is responsible for the mechanical and biochemical properties of bone
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tissue. Some of the noncollagenous proteins include bone matrix proteins, growth factors,
cytokines and osteocalcin. Osteocalcin or bone-carboxyglutamic acid-containing protein (bone
Gla protein) accounts for 10-20% of the noncollagenous proteins and is closely associated with
the mineral or inorganic phase [5]. The exact function of osteocalcin is unknown; however, it
might play a role in inhibiting osteoblast function, attracting osteoclasts to sites of bone
resorption and regulating the rate of mineralization [5, 8]. Growth factors and cytokines such as
transforming growth factor-β, insulin-like growth factors, osteoprotegerin, tumor necrosis factors
and interleukins are present in very small quantities and are believed to regulate cell
differentiation, activation, growth and turnover rates. Bone matrix proteins such as osteopontin
and bone sialoprotein contain RGD sequences, which are amino acids recognized by integrins,
and are believed to play a role in cell adhesion [5].
There are three types of bone cells located within the organic matrix: osteoclasts,
osteoblasts and osteocytes. Osteoclasts are multinucleated cells formed from the fusion of
mononuclear progenitors of the monocyte/macrophage family [9]. They are active agents in
bone resorption and are responsible for remodeling bone [5].
Osteoblasts are derived from mesenchymal stem cell precursors. These precursors are
capable of following one of three pathways: 1) remain as active osteoblasts, 2) differentiate into
osteocytes or 3) become relatively inactive and form bone lining cells [7]. Regulation of
osteoblast differentiation is unclear; however, the transcription factor Runx2, also known as
Cbfa1, is the earliest known and most specific marker of osteoblast differentiation [10]. The
function of osteoblasts is primarily as bone forming cells, and they operate by synthesizing and
secreting structural components of the bone matrix as well as governing bone metabolism.
Osteoblasts release minerals, growth factors and enzymes into the bone matrix, ultimately
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producing an osteoid. An osteoid is the unmineralized bone matrix containing calcium and
phosphate depositions in the form of hydroxyapatite crystals. Once an osteoblast has synthesized
an osteoid and mineralized it, the osteoblast can become enveloped in this matrix and
differentiate into an osteocyte [3, 5]. Cells of the osteoblast lineage can also initiate bone
resorption by secreting molecules that regulate osteoclast differentiation [8].
Osteocytes are derived from mesenchymal stem cell precursors and are found in abundant
amounts in mineralized bone matrix. They are also found in bone marrow stroma, soft tissues
and periosteum. Their function is poorly understood, but osteocytes may form cell networks,
enabling them to transduce mechanical stimuli from the periphery to the center of the bone [3, 5].

1.2.3 Bone Mass
Bone mass is determined by the amount of bone remodeling and bone growth occurring
within the skeletal system and by the amount of mineralized bone tissue a person has at their
current stage in life. Bone mass accumulation entails two processes that cover a life span: 1) the
rapid accumulation of bone mass in childhood due to bone growth (peaks around 20-30 years)
and 2) maintenance of existing bone mass by bone remodeling. Accumulation is generally due
to sexual maturation, linear growth and genetic and nutritional factors. Bone mass is typically
lost slowly throughout adulthood due to the loss of bone mineral during bone remodeling [11].
To detect a decrease in bone mass, the bone mineral density (BMD) of a person can be
measured. BMD can be measured in a number of ways to assess onset of bone disease.
Histomorphometry utilizes a bone biopsy, an invasive procedure, which is both expensive and
has a long turn-around time. This method uses the biopsy specimen to describe the trabecular
configuration and connectivity [6, 12, 13]. Densitometry is a noninvasive procedure; however, it
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is slow when it comes to detecting changes [6]. This method measures bone mineral density by
taking a two-dimensional measure of the mineral content of bone in a particular skeletal region
[3]. A noninvasive, inexpensive method capable of providing direct information relies on the use
of biochemical markers measured via blood or urine. The biochemical markers include byproducts produced during the synthesis of new bone, enzymes or proteins secreted by cells
involved in the remodeling process or the breakdown of products generated in the resorption of
old bone. The use of the biochemical markers, while a valid approach, can be problematic. The
detection of markers varies with the stage of bone remodeling that a person is in. The bone
remodeling cycle can be altered by exercise, bed rest, dieting extremes, the menstrual cycle and
the season of the year. While this method is capable of detecting large changes in diseases such
as Paget’s disease of bone, the nature of the remodeling cycle makes it difficult to detect minor
changes related to diseases such as osteoporosis [6]. The gold standard for evaluating changes in
bone mass due to osteoporosis is dual-energy X-ray absorptiometry (DEXA). DEXA operates
by precisely measuring central bone mass, typically at the spine and hip location [14, 15].

1.2.4 Bone Maintenance and Remodeling
Bone remodeling is a continual process that involves two cell types: osteoblasts and
osteoclasts (Figure 1-1 [16]). Most bone acquisition occurs by chondrocytes laying down and
calcifying a matrix. The matrix is then remodeled by resorption through osteoclasts and
formation via osteoblasts into new bone. The activation of the two cell types are linked so as to
keep the bone remodeling cycle in balance [11].
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Figure 1-1: Bone remodeling cycle. Osteoclasts are recruited to the site of remodeling
to resorb bone. Following resorption, osteoblasts fill the newly remodeled area, forming
new bone.

Typically, bone resorption by osteoclasts takes 7-10 days and formation by osteoblasts
takes 2-3 months. Approximately 10% of total bone is replaced every year, with the remodeling
occurring on the bone surfaces. Roughly 25% of cancellous bone becomes remodeled every
year, despite the fact that it only makes up 20% of the skeletal mass. On the other hand, only 3%
of cortical bone becomes renewed each year. After the age of 35-40, there is a normal net loss of
bone after each remodeling cycle because the amount of bone formed is less than the amount
resorbed [6].
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1.2.5 Pathology of Bone
A disturbance or uncoupling of bone cell activity leads to a net loss of bone density. This
in turn causes an imbalance in the cycle, resulting in excessive osteoclast or osteoblast activity.
For example, osteosclerosis and osteopetrosis are characterized by an increase in bone mass, the
former resulting from a gain of function in osteoblasts and the latter resulting from a loss of
function in osteoclasts [10, 17]. Rickets and osteomalacia are skeletal disorders related to
impaired skeletal mineralization. They are characterized by an excess of osteoid, resulting from
a net deficiency of mineral in the matrix [3].
Elevated osteoclast numbers and increased activity result in an increase in bone
resorption and disease. An example of this is osteoporosis, characterized by low bone mass,
microarchitectural deterioration of bone tissue and an increased risk for fractures [10, 14, 15, 17].
The imbalance is generally caused by bone resorption exceeding bone formation, due to, for
example, estrogen deficiency in post-menopausal women and growth hormone (GH) deficiency
[11]. Another instance in which there is excessive activity by osteoclasts is Paget’s disease of
bone. The cause of Paget’s disease is unknown, but genetic factors may play an important role
in the onset. Both conditions are more common in the elderly, with osteoporosis occurring more
frequently in females and Paget’s disease of bone occurring more frequently in males [18-20].

1.3 Bone growth factors and regulators
A variety of local and systemic factors regulate the growth, formation and remodeling of
bone, including the proliferation and differentiation of some cell types such as osteoblasts. Some
of these factors include hormones such as thyroid hormone and estrogen as well as growth
factors and cytokines [6]. The synthetic glucocorticoid dexamethasone promotes and regulates
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proliferation and differentiation through regulating gene expression of assorted binding proteins
such as insulin-like growth factor binding proteins (IGFBP) and insulin-like growth factor-I and
-II (IGF-I and -II) [21]. Current studies have shown that a novel protein, PAPP-A, affects the
bioavailability of IGF-I, thus making it a potential regulator of proliferation [22].

1.3.1 Insulin-like Growth Factor Family (IGF)
The IGF family consists of two polypeptide ligands (IGF-I and IGF-II), two types of cell
membrane receptors (IGF-IR and IGF-IIR), six binding proteins (IGFBP-1 through IGFBP-6)
and a group of IGFBP proteases [23, 24]. Together, these molecules play an important role in
regulating cell proliferation, differentiation, apoptosis and transformation [23-26].

a. Insulin-like Growth Factors
Both IGF-I and IGF-II were identified in 1957 and can act systemically as a hormone and
locally as autocrine/paracrine factors [25, 27]. They each consist of a single chain polypeptide
and are approximately 7 kDa in size [11, 25]. They have mitogenic and antiapoptotic actions
when freely available; however, less than 1% of IGFs circulates in the free form. The rest of the
time, IGFs are typically found in conjunction with a binding protein, preventing the IGFs from
binding to their cellular receptors [11, 25, 28].

Insulin-like Growth Factor-I (IGF-I)
IGF-I is produced primarily by hepatocytes in the liver but also by the brain, muscle and
bone [11, 25]. IGF-I can stimulate cell proliferation and differentiation and can inhibit
apoptosis, causing an impact on tumor growth [24, 26]. Expression of the IGF-I gene, located on

9

chromosome 12, is primarily regulated by growth hormone (GH) [11, 24]. In addition,
expression of IGF-I is influenced by other hormones such as estrogens, follicle stimulating
hormone (FSH), human chorionic gonadotropin (HCG), andrenocorticotropic hormone (ACTH),
luteninizing hormone (LH) and thyrotropin as well as growth factors such as fibroblast growth
factor (FGF), platelet-derived growth factor (PDGF) and epidermal growth factor (EGF). Diet
and nutrition also affect the levels of IGF-I in circulation [24].
IGF-I acts as a mitogen by increasing DNA synthesis and stimulating the expression of
cyclin D1, thus accelerating the progression of the cell cycle from G1 to S phase [23, 24]. IGF-I
also acts as an anti-apoptotic agent by stimulating the expression of Bcl proteins and suppressing
expression of Bax, ultimately blocking initiation of the apoptotic pathway [24]. IGF-I has an
anabolic effect on osteoblasts by increasing cell numbers and matrix production. It also
stimulates osteoclast formation and activity [11, 26].
Adult levels of IGF-I normally range from 100-200 ng/mL [24]. When IGF-I is in
circulation, 90-95% of the time it is in a complex with Insulin-like Growth Factor Binding
Protein-3 (IGFBP-3) and an acid labile subunit (Figure 1-2 A), leaving only a small amount free
in circulation (Figure 1-2 B) [11, 28]. IGF-I levels change with age, increasing slowly from birth
until puberty. There is a surging at puberty when it plays a role in growth-plate mediated
growth, and then a decline with age. Level changes like these are regulated by GH [24].
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A)

B)

Figure 1-2: A) IGFBP-4 binds IGF-I, preventing IGF-I from
binding to its receptor on the osteoblast cell surface. B) Free
IGF-I binding to its receptor and the osteoblast, thus activating
the osteoblast.

Insulin-like Growth Factor-II (IGF-II)
Like IGF-I, IGF-II is capable of regulating cell proliferation and differentiation. The
primary regulator of IGF-II gene expression, located on chromosome 11, remains unclear. Adult
blood levels of IGF-II range between 400 and 600 ng/mL and circulating levels remain relatively
stable after puberty. Regardless of its elevated levels, IGF-II plays a less important role in
postnatal growth [24]. Evidence suggests that IGF-II plays a crucial regulatory role during
embryonic and fetal development [23, 24]. After birth, the role of IGF-II is steadily replaced by
that of IGF-I [24].
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b. Cell Membrane Receptors
There are two IGF receptors, IGF-IR and IGF-IIR. Both are glycoproteins and are
located on the cell membrane [23, 24]. Their structure and function differ completely. IGF-I
and -II share a 62% homology in their amino acid sequences and share structural similarities
among themselves as well as with proinsulin. Because of this, IGFs and insulin are able to crossbind to each other’s receptor, but with a much weaker binding affinity [24, 28].

Insulin-like Growth Factor-I Receptor (IGF-IR)
The IGF-I receptor is a tyrosine kinase cell-surface receptor and consists of two identical
alpha-subunits and two identical beta subunits [23, 24, 29, 30]. IGF-IR has three main functions:
stimulation of mitogenesis in many different cell types, cellular protection from apoptosis and
cellular transformation. The expression of IGF-IR is regulated by steroid hormones and growth
factors such as estrogens, thyroid hormones, glucocorticoids, GH, LH, EGF, FGF and PDGF. In
addition, nutrition can also impact IGF-IR levels [23, 24, 29]. Tumor suppression gene products
such as Wilms’ tumor protein and wild-type p53 inhibit expression of IGF-IR. Two signal
transduction pathways have been identified for IGF-IR. The first activates the Ras protein, Raf
protein and mitogen activated protein kinase cascade (Ras/Raf/MAP kinase cascade) and the
other pathway, involves phosphoinositol-3-kinase. Other pathways besides the two mentioned
above may exist [24].
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Insulin-like Growth Factor-II Receptor (IGF-IIR)
The IGF-II receptor is monomeric, and contains three ligand-binding regions located
within the extracellular domain of the receptor. One binding domain is used for IGF-II and the
other two for proteins containing mannose-6-phosphate, including rennin, proliferin,
thyroglobulin and transforming growth factor-β. IGF-IIR does not have tyrosine kinase activity
and only binds to IGF-II. Given that binding of IGF-II to IGF-IIR results in degradation of IGFII, IGF-IIR acts as an antagonist to IGF-II, reducing the biological activity of IGF-II. Little is
known about the regulation of IGF-IIR expression [24].

c. Insulin-like Growth Factor Binding Proteins (IGFBP)
There are six IGFBPs that can have both inhibitory and stimulatory effects on the
regulation of IGF-I. The regulation of their gene transcription is complex and tissue specific
[24]. Hormones such as thyroid hormone, estrogens, parathyroid hormone, glucocorticoids,
insulin, vitamin D, cortisol, FSH and GH regulate their expression. They are also regulated by
growth factors such as TGF-β, EGF, PDGF and FGF. In addition, IGFBPs can also be regulated
by IGFs themselves as well as PAPP-A [24]. The six IGFBPs undergo extensive posttranslational modifications by phosphorylation and proteolysis, which affect their binding
affinities for IGFs [24].
IGFBPs can have multiple functions and have the ability to act in an IGF independent or
IGF dependent manner. (Table 1-1 [24, 25, 27, 28]). IGFBPs function by inhibiting the actions
of IGFs and suppressing cell proliferation or by enhancing IGF actions hence stimulating cell
proliferation. IGFBPs play three major roles when binding to IGFs: 1) transporting IGFs, 2)
protecting IGFs from degradation and 3) regulating the interaction between IGFs and IGF
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receptors [24]. By protecting IGF from degradation, the bioavailability of IGF is increased in
local tissue [23-25].
Generally, IGFBPs have higher binding affinities to IGFs than does IGF-IR, therefore
blocking access to the receptor and suppressing IGF action [25, 31]. However, binding protects
IGFs from degradation and that protection can enhance the action of IGFs by increasing their
bioavailability in local tissue. Proteases from each of the major protease families (i.e. serine,
aspartic, cysteine and metalloproteinases) are capable of degrading IGFBPs in vitro; yet few of
them have been convincingly shown to degrade IGFBPs in physiological systems [31].

14

Table 1-1: Functions of Insulin-like Growth Factor Binding Proteins
(IGFBPs) with respect to effect on IGFs
IGFBPs
IGFBP-1

IGFBP-2

IGFBP-3

IGFBP-4
IGFBP-5

IGFBP-6

Function
• Suppresses/enhances IGF actions
• Binds to cell surface receptors or attaches to cell
surface, thus reducing binding affinity for IGFs
resulting in release of free IGFs
• Suspected to have IGF-independent effects on
cellular activities such as cell adhesion and
migration
• Suppresses/enhances IGF actions
• Binds to cell surface receptors or attaches to cell
surface, thus reducing binding affinity for IGFs
resulting in release of free IGFs
• Suspected to have IGF-independent effects on
cellular activities such as cell adhesion and
migration
• Suppresses/enhances IGF actions
• Binds to cell surface receptors or attaches to cell
surface, thus reducing binding affinity for IGFs
resulting in release of free IGFs
• Regulates mitogenic action of IGFs
• Can inhibit IGFs antiapoptotic effect
• Has IGF-independent inhibitory effect on cell
growth
• Inhibits mitogenic actions of IGFs
• Specifically binds to IGF-I, preventing it from
binding to IGF receptors
• Suppresses/enhances IGF actions
• Binds to cell surface receptors or attaches to cell
surface, thus reducing binding affinity for IGFs
resulting in release of free IGFs
• Suspected to have IGF-independent effects on
cellular activities such as cell adhesion and
migration
• Inhibits mitogenic actions of IGFs

Mode of Regulation
(with respect to effect
on IGFs)
Phosphorylation

Proteolysis

Proteolysis

Proteolysis
Proteolysis
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1.3.2 Pregnancy Associated Plasma Protein A (PAPP-A)
PAPP-A was discovered in 1974 along with several other proteins isolated from
pregnancy serum [32-35]. PAPP-A could be detected in pregnancy serum as early as 4-6 weeks
and was localized to the syncytiotrophoblast tissue of the placenta and the placental cells [34, 3638]. Its levels gradually increase until the third trimester, at which time it is present in pooled
serum at approximately 50mg/L. Following birth, PAPP-A levels drastically decrease. In nonpregnant individuals, the protein is virtually undetectable [34, 36, 38]. Since its initial discovery,
PAPP-A has been found in and secreted from several other tissues, including human osteoblasts,
skin fibroblasts, vascular smooth muscle cells, granulosa cells, the Graafian follicle, corpus
luteum and testes, all at exceptionally low levels [34, 35, 38].
The human PAPP-A gene is located on chromosome 9q33.1 and shares a high degree of
homology among mammalian species [39]. PAPP-A exhibits an elongated zinc-binding motif at
position 482-492 and a methionine residue at position 556, both of which are highly conserved
components of the metzincin superfamily of metalloproteinases. PAPP-A specifically is the
founding member of the pappalysin family within the metzincin superfamily [40]. A second
member recently joined this particular family, PAPP-A2, sharing 45% of its residues with PAPPA when in mature forms. PAPP-A2 is believed to cleave IGFBP-5 instead of IGFBP-4 [41].
Initially, the physiological role both inside and outside pregnancy was unknown. Since
its discovery, low PAPP-A serum levels are being implicated as an indicator of Down’s
syndrome during the first semester as well as Cornelia de Lange Syndrome. In addition,
attempts are being made to use PAPP-A levels along with a series of other biomarkers to detect
miscarriages and other chromosomal abnormalities [36]. In humans, maternal levels of PAPP-A
correlate with birth weight [42]. PAPP-A null mice are normal but proportionally smaller
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compared to their wild-type littermates, a phenotype analogous to IGF-II null mice [42, 43]. In
addition, PAPP-A cleaves IGFBP-4 at one site into two halves in the presence of IGFs (Figure 13) and can act in an autocrine or paracrine manner. This proteolytic activity increases the
bioavailability of the IGFs, particularly IGF-I [41]. Furthermore, PAPP-A cleaves IGFBP-5, but
only in the absence of IGFs [42]. The activity of PAPP-A appears to be partially governed by
pH. The protein is most active at a pH slightly higher than physiological pH levels and loses its
activity around pH 6 [40].
Other roles of PAPP-A, aside from human reproduction, include atherosclerotic plaque
development, wound healing and bone remodeling [22]. Purified PAPP-A increases matrix
mineralization in human adult mesenchymal stem cells in the presence of recombinant human
bone morphogenic protein-2 (BMP-2) but in the absence of dexamethasone, up-regulating key
genes. Furthermore, purified PAPP-A induces an angiogenic effect in the chick chorioallontoic
membrane, a quality essential for bone regeneration [44]. No biological functions, other than
those involving PAPP-A’s proteolytic activity, have been identified.
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Figure 1-3: Action of insulin-like growth factor binding
protein-4 (IGFBP-4) and pregnancy associated plasma
protein A (PAPP-A) on insulin-like growth factor-I (IGF-I).

During human pregnancy, 99% of PAPP-A is found in a complex with the proform of
eosinophil major basic protein (proMBP). The 500 kDa PAPP-A/proMBP is a heterotetrameric
2:2 complex connected by a covalent disulfide bond. The other 1% of the time, PAPPA/proMBP is found in a 2:1 complex [37, 38, 45]. Outside of pregnancy, PAPP-A exists
primarily as a 400 kDa homodimer but in vitro analysis shows the protein can be further reduced
to a 200 kDa monomer [22, 41].
The protein complexed with PAPP-A is the immature form of the major basic protein
(MBP). Mature MBP is a highly basic cytotoxic protein stored in the granules of the eosinophil
leukocyte. The pro- piece of proMBP is highly acidic and masks the cytotoxicity of the MBP
during processing in the eosinophil. During pregnancy, the majority of proMBP is synthesized
in the placental X cells and functions as a proteinase inhibitor in vivo [37, 45-47].
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1.4 Osteoblast cell models
1.4.1 MG-63 cells
MG63 cells are derived from a human osteosarcoma and are representative of a human
osteoblast cell line. This cell line is well characterized and is readily available. These cells
exhibit osteoblastic traits such as the ability to synthesize alkaline phosphatase, osteocalcin and
type I collagen [48]. They are also capable of producing cyclic AMP in response to parathyroid
hormone and prostaglandin E2.

When treated with 1,25-(OH)2D3 (vitamin D3), alkaline

phosphatase, fibronectin, collagen, cAMP and osteocalcin synthesis increased, supporting the
idea that MG-63 cells are capable of differentiating into an osteoblast-like phenotype in response
to hormones [49]. MG63 cells, when grown on F-12/MEM medium with 10% Fetal Bovine
Serum exhibit a relatively fast growth rate, doubling every 36 hours and having a saturation
density of 60,000 cells/cm2 [48, 50]. MG-63 cells do not contain an endogenous level of PAPPA [22].

1.4.2 Human Adult Mesenchymal Stem Cells (hAMSC)
Human bone marrow contains hematopoietic and non-hematopoietic cells [51, 52]. The
precursors of non-hematopoietic cells are known as mesenchymal stem cells or marrow stromal
cells and can be isolated from the bone marrow stroma by aspiration under local anesthesia [51,
53]. They have the ability to differentiate into tendon, ligament, bone, cartilage, stroma, adipose
and muscle, when in appropriate culture conditions (see figure 1-4 [54]) [21, 55].
These cells proliferate when exposed to fetal bovine serum and are capable of
differentiation in osteogenic supplement (OS), which includes dexamethasone, β-
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glycerophosphate and ascorbic acid-2-phosphate [53, 55]. Their differentiation is characterized
by increased alkaline phosphatase activity, formation of cAMP and increased expression of
osteogenic marker genes such as osteonectin, osteoponin and osteocalcin [55]. In addition to
their ability to differentiate into various cell types, mesenchymal stem cells express cytokines,
growth factors, and cell surface molecules so they are classified as multipotent cell populations
[52].

Figure 1-4: Differentiation potential of Mesenchymal stem cells when
subjected to appropriate culture conditions.

20

1.5 Thesis Goals
Hypothesis: PAPP-A induces proliferation and differentiation of MG-63 cells and hAMSC, and
it requires proteolytic activity to function.
Rationale: PAPP-A acts by proteolytically cleaving IGFBP-4 from IGF-I, thus freeing IGF-I to
bind to its receptor on the cell surface. Once bound, IGF-I turns on a series of molecules in a
signaling pathway that ultimately enhances cellular proliferation and differentiation. Purified
PAPP-A functions in matrix mineralization and up-regulating key genes; however, the
proliferative capabilities of purified PAPP-A have not been studied [44].
Objectives: The human osteosarcoma cell line (MG63 cells) and human Adult Mesenchymal
Stem Cells (hAMSC) will be used as a model system for evaluating the development of
osteoblast-like cells. By testing the proliferation and differentiation of these cells, I will evaluate
the ability of several forms of PAPP-A to regulate their growth and development.
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CHAPTER 2- PAPP-A DOES NOT INDUCE CELLULAR PROLIFERATION

2.1 Introduction

Insulin-like growth factors (IGFs) play an important role in growth by stimulating
cellular proliferation [36]. IGF-I and –II are capable of binding to the IGF-I receptor on the cell
surface, stimulating cell growth and proliferation [56]. The ability of IGFs to act is regulated by
a series of binding proteins, known as the insulin-like growth factor binding proteins (IGFBP).
Currently, there are six IGFBPs that regulate the bioavailability and actions of IGFs and in turn,
there are groups of proteases capable of regulating IGFBPs. One such IGFBP protease is PAPPA. PAPP-A functions by proteolytically cleaving binding proteins, particularly IGFBP-4, from
IGFs. This increases the bioavailability of the growth factor, allowing it to bind to its receptor
on the cell surface.[36].
Previous studies have shown that mice lacking both copies of the IGF-I or IGF-II gene
show developmental delays, weighing approximately 60% of the birth weight of their normal
littermates. Some IGF-I (-/-) mice died shortly after birth, while others survived until adulthood.
Those that did manage to survive had multiple developmental deficiencies resulting in delays in
ossification, generalized organ hypoplasia and deviations in the central nervous system [57, 58].
Mice heterozygous for IGF-I, IGF-I (+/-), also showed a decrease in birth weight, 10-20%. Bone
mineral density and size were also distinguishably smaller when compared to their wild-type
littermates. In addition, cell cultures from these mice showed decreased cell growth and
proliferation [59].

These studies illustrate the importance of the IGF family in bone

development.
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The proliferation response in regards to PAPP-A has not been previously studied to my
knowledge. In the present study, my goal was to evaluate the ability of PAPP-A to stimulate
proliferation in vitro of MG-63 cells and human adult mesenchymal stem cells. To do this, cells
were incubated with PAPP-A for specific periods of time. Proliferation was measured via the
CyQUANT cell proliferation assay and BrdU incorporation. I demonstrate that in an in vitro
setting, commercially available PAPP-A does not increase proliferation.

2.2 Materials and Methods

Materials

Human Adult Mesenchymal Stem Cells (hAMSC) were obtained from Cambrex Bio
Science (Walkersville, MD) and maintained in mesenchymal stem cell basal medium
supplemented with mesenchymal stem cell growth supplement, L-glutamine, penicillin and
streptomycin obtained from Cambrex and prepared according to manufacturer’s specifications.
Cambrex certified hAMSC positive for osteogenic, chondrogenic and adipogenic potential.
Human MG-63 osteosarcoma cells were obtained from American Type Culture Collection
(Manassas, VA) and maintained in F12 nutrient mixture HAM and Minimum Essential Medium
supplemented with fetal bovine serum, penicillin and streptomycin. F12 nutrient mixture HAM,
Minimum Essential Medium and the fetal bovine serum were purchased from Hyclone (Logan,
UT) and the penicillin and streptomycin were purchased from Gibco, a subdivision of Invitrogen
(Carlsbad, CA). Trypsin/EDTA 0.05% was obtained from Hyclone (Logan, UT). Purified
PAPP-A protein was purchased from Advanced Immunochemical Inc. (Long Beach, CA).
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2.2.1 Cell culture

For proliferation studies, hAMSC or MG-63 cells were seeded in complete growth
medium prior to starvation period. Cells were starved in serum-free medium for 18 or 48 hours
respectively [44]. hAMSC or MG-63 cells were then treated with PAPP-A in serum-free growth
medium for 24, 48 or 72 hours unless otherwise noted. All cells were maintained at 37°C under
a humidified atmosphere containing 95% air and 5% CO2. hAMSC and MG-63 cultures were
passaged when subconfluent by treatment with Trypsin/EDTA 0.05%.

2.2.2 Cell proliferation assessment

For the CyQUANT method, cells were collected at their experimental time points and
frozen for a minimum of 24 hours followed by a brief thawing period. Cells were lysed by
addition of a buffer containing the CyQUANT GR dye. Fluorescence was measured using a
HTS 7000 BioAssay Reader (Perkin Elmer; Wellesley, MA) with the excitation at 485 +/- 10 nm
and emission being detected at 530 +/- 12.5 nm. A minimum of three controls was used for each
experiment: complete growth medium (positive control), serum free medium (negative control)
and an addback control (a starvation period in serum free media of 18 hours for hAMSC or 48
hours for MG-63 cells followed by culture in complete growth medium).

For BrdU

incorporation, BrdU was added to the media for 24-72 hours prior to the end point. The assay
was performed according to the manufacturer’s protocol and assessed on a BIO-RAD Model
3550 Microplate Reader (GMI, Inc; Ramsey, MN). A series of controls were conducted with
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each experiment: complete growth medium, serum-free medium, and addback control in addition
to the controls listed in the manufacturer’s protocol.

2.2.3 Statistical analysis

For all assays, statistics were performed using the GraphPad Prism Program version 4.0b
(San Diego, CA). For proliferation assays, a one-way Analysis of Variance (ANOVA) was
conducted followed by the Bonferroni post hoc test. A p-value of ≤0.05 was considered
significant.

2.3 Results and Discussion

Prior to assessment of PAPP-A’s ability to stimulate proliferation of hAMSC and MG-63
cells, serum starvation experiments were conducted. Experimental procedure and results can be
found in appendix B (pages 53-56). All cells were seeded in complete serum for 24 hours,
followed by a starvation period and completed with incubation in serum free medium containing
PAPP-A. Results were analyzed via CyQUANT. Based on the results obtained, a starvation
period of 48 hours was selected for MG-63 cells and 18 hours for hAMSC [44].
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2.3.1 Proliferation of MG-63 cells in response to PAPP-A

To determine whether PAPP-A had the ability to induce proliferation in MG-63 cells in
vitro, cells were cultured in commercially available purified PAPP-A. To account for potential
masking by fetal bovine serum (FBS) of PAPP-A’s activity, cells were cultured for 24 hours in
F12/MEM with 10% FBS to allow for attachment followed by a starvation period of 48 hours
(appendix B, pages 53-56) in F12/MEM without FBS. Experimental wells were cultured in
F12/MEM without FBS but with varying concentrations of PAPP-A for a period of 24 hours.
Cellular proliferation was analyzed via two methods: CyQUANT cell proliferation assay and
measurement of BrdU incorporation.
Four concentrations of purified PAPP-A were selected and cells were incubated in serum
free medium for 24 hours containing the PAPP-A. Figures 2-1 A and B depict proliferation
measurement based on the CyQUANT cell proliferation method. The levels of proliferation of
cells treated with purified PAPP-A are significantly less than the addback control. The purified
PAPP-A used is found in a complex with its physiological inhibitor, proMBP. In this form,
PAPP-A is not free to proteolytically cleave IGFBP-4 from IGF-I, explaining the results seen
here. This suggests that the commercially available form of purified PAPP-A is incapable of
stimulating cellular proliferation in vitro.
Additional studies were conducted using two recombinant forms of PAPP-A: a wild-type
version theoretically capable of cleaving IGFBP-4 from IGF-I due to the absence of the proMBP
protein and a protease deficient version lacking its proteolytic domain. Variation between
experiments was observed and in most cases, it appears as if the addition of PAPP-A decreased
levels of proliferation. The results of these studies, however, do not clearly exhibit a statistically
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significant increase or decrease in proliferation in response to the recombinant forms of PAPP-A.
This outcome may be attributed to the method of isolation of the recombinant proteins. The
proteins were extracted from cells that were grown in medium containing serum. While the
amount of serum may be negligible, it may be sufficient to throw off the results. In addition, the
components of serum aside from albumin content are not fully known. It is possible that the
serum may contain proMBP, which in turn could bind to the recombinant PAPP-A. This would
prevent the PAPP-A from performing its proposed activities. Results and experimental set up for
these studies can be found in appendix B on pages 56-63.
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Figure 2-1: Growth of MG-63 cells with PAPP-A. MG-63 cells were seeded
in 10% FBS for 24 hours. After initial 24 hour period, cells were starved for 48
hours. Following the starvation period, commercially available PAPP-A was
added to the wells for a total of 24 hours. A) Controls and B) purified PAPP-A.
Results were analyzed via CyQUANT and are represented as units of
fluorescence per mm2. Statistical significance is reported as compared to the
addback control: * = p≤0.05 and ** p≤0.001 as determined via one-way
ANOVA and Bonferroni post hoc test. n = 3; mean ± SEM. FBS = Fetal
Bovine Serum. Addback = starvation for 48 hours with 0% FBS, followed by
addition of 10% FBS for 24 hours.
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2.3.2 Proliferation of hAMSC in response to PAPP-A

To determine whether PAPP-A had the ability to induce proliferation in hAMSC in vitro,
cells were cultured in 200 ng/mL purified PAPP-A. To account for the potential masking by
FBS of PAPP-A’s activity, cells were cultured for 24 hours in mesenchymal stem cell growth
medium (MSCGM) containing FBS to allow for attachment followed by a starvation period of
18 hours [44] in mesenchymal stem cell basal medium (MSCBM) lacking the FBS component.
Experimental wells contained cells cultured in MSCBM with 200 ng/mL PAPP-A for a period of
72 hours. Cellular proliferation was analyzed via two methods: CyQUANT cell proliferation
assay and measurement of BrdU incorporation. Figures 2-2A and B depict proliferation
measurement based on the CyQUANT cell proliferation method and BrdU incorporation,
respectively, based on analysis of 3 replicate experiments for each method. Both methods of
assessment show that there is a statistically significant reduction in proliferation in cells treated
with PAPP-A, when compared to the complete serum and addback controls after 72 hours of
incubation. The levels of proliferation of cells treated with PAPP-A are comparable to cells
treated with basal medium. This suggests that the commercially available form of purified
PAPP-A is incapable of stimulating cellular proliferation in vitro. PAPP-A acts by cleaving
IGFBP-4 from IGF-I, allowing IGF-I to bind to its receptor on the cell surface and stimulate the
proliferation signaling pathway.

The PAPP-A used for these studies is found in a

heterotetrameric complex with its physiological inhibitor, proMBP. In this form, PAPP-A is not
free to proteolytically cleave IGFBP-4 from IGF-I, explaining the results seen here.
Additional studies were conducted using two recombinant forms of PAPP-A: a wild-type
version theoretically capable of cleaving IGFBP-4 from IGF-I due to the absence of the proMBP
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protein and a protease deficient version lacking its proteolytic domain. Variation between
experiments was observed and in some cases, the controls did not work (figures S-9, A and B).
The results of these studies do not clearly exhibit a statistically significant increase or decrease in
proliferation in response to the recombinant forms of PAPP-A. This outcome may be attributed
to the method of isolation of the recombinant proteins. The proteins were extracted from cells
that were grown in medium containing serum. While the amount of serum may be negligible, it
may be sufficient to throw off the results. In addition, the components of serum aside from
albumin content are not fully known. It is possible that the serum may contain proMBP, which
in turn could bind to the recombinant PAPP-A. This would prevent the PAPP-A from
performing its proposed activities. Results and experimental set up for these studies can be
found in appendix B on pages 64-69.
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Figure 2-2: Growth of hAMSC with PAPP-A. hAMSC were treated with 200 ng/mL
purified PAPP-A in basal medium for 72 hours. A) CyQUANT analysis and B) BrdU
incorporation were used to determine proliferative response. Results are shown as units of
fluorescence (arbitrary unit) and % BrdU incorporation respectively. Both A and B are
normalized to the addback control. Mean of 3 independent experiments containing 8 samples
each ± SEM. Different letters represent statistical significance between treatments, p≤0.05 as
determined via one-way ANOVA and Bonferroni post hoc test. MSCGM = Mesenchymal
Stem Cell Growth Medium, BM = Basal Medium, Addback = starvation for 18 hours with
BM, followed by addition of MSCGM for 72 hours.
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CHAPTER 3- PAPP-A INDUCES DIFFERENTIATION IN VITRO

3.1 Introduction

Insulin-like growth factors (IGFs) play an important role in development by stimulating
cellular differentiation [36]. The ability of IGFs to act is modulated by a series of binding
proteins, known as the insulin-like growth factor binding proteins (IGFBP). Currently, there are
six IGFBPs that regulate the bioavailability and actions of IGFs and in turn, there are groups of
proteases capable of regulating IGFBPs. One such IGFBP protease is PAPP-A. PAPP-A
functions by proteolytically cleaving binding proteins, particularly IGFBP-4, from IGFs. This
increases the bioavailability of the growth factor, allowing it to bind to its receptor on the cell
surface [36].
A recent study involving PAPP-A null mice resulted in functional yet proportionally
smaller mice when compared to their wild-type littermates, a phenotype analogous to IGF-II null
mice [42, 43]. Recently, a study using commercially available purified PAPP-A increased
matrix mineralization in human adult mesenchymal stem cells in the presence of recombinant
human bone morphogenic protein-2 (BMP-2) but in the absence of dexamethasone, upregulating key genes. In addition, purified PAPP-A was shown to induce an angiogenic effect in
the chick chorioallontoic membrane, a quality essential for bone regeneration [44]. Biological
functions not involving PAPP-A’s proteolytic activity have yet to be identified.
My goal was to confirm the differentiative ability of purified PAPP-A in an in vitro
setting. Utilizing real-time RT-PCR, I was able to confirm the up-regulation of Runx2 gene
expression in hAMSC in the absence of an osteogenic supplement when treated with PAPP-A.
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In addition, I was able to demonstrate the up-regulation of an additional osteoblast gene marker,
alkaline phosphatase, under the same treatment conditions at a later time point.

3.2 Materials and Methods

Materials

Human Adult Mesenchymal Stem Cells (hAMSC) were obtained from Cambrex Bio
Science (Walkersville, MD) and maintained in mesenchymal stem cell basal medium
supplemented with mesenchymal stem cell growth supplement, L-glutamine, penicillin and
streptomycin obtained from Cambrex and prepared according to manufacturer’s specifications.
Cambrex certified hAMSC to be positive for osteogenic, chondrogenic and adipogenic potential.
Trypsin/EDTA 0.05% was obtained from Hyclone (Logan, UT).

Dexamethasone, β-

glycerophosphate and ascorbic acid-2-phosphate were obtained from Sigma-Aldrich (St. Louis,
MO). Purified PAPP-A protein was purchased from Advanced Immunochemical Inc. (Long
Beach, CA). QIAshredder, Rneasy Mini Kit and RNase-Free DNase set were obtained from
Qiagen (Valencia, CA). TaqMan® One-Step PCR Master Mix Reagents Kit and 18s ribosomal
primers and probes were purchased from Applied Biosystems (Long Beach, CA). Target gene
primers and probes were purchased from Integrated DNA Technologies (Coralville, IA).
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3.2.1 Cell culture

For differentiation studies, hAMSC or MG-63 cells were seeded in complete growth
medium prior to treatment with 200 ng/mL PAPP-A for 6, 12, 18, 24, 48 or 96 hours. No
starvation period was needed. To induce osteogenic differentiation of hAMSC or MG-63 cells,
100 nm dexamethasone, 10 mM β-glycerophosphate and 0.05 mM ascorbic acid-2-phosphate
were added to their respective complete growth media. All cells were maintained at 37°C under
a humidified atmosphere containing 95% air and 5% CO2. hAMSC and MG-63 cultures were
passaged when subconfluent by treatment with Trypsin/EDTA 0.05%

3.2.2 RNA extraction

Total RNA was extracted using the QIAshredder and RNeasy Mini Kit according to
manufacturer’s specifications followed by treatment with RNase-Free DNase treatment to
eliminate any residual genomic DNA.

3.2.3 Real-time RT-PCR analysis

Cells were harvested at various time points (6, 12, 18, 24, 48 and 96 hours) followed by
RNA extraction. Real-time RT-PCR was performed using Taqman® One-step RT-PCR Master
Mix Reagents Kit. 1 µL of total RNA was added per 39 µL reaction with sequence specific
primers and Taqman® probes. Sequences for all target gene primers and probes are shown in
table 1. 18s ribosomal primers and probes were designed and purchased from Applied
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Biosystems. Real-time RT-PCR assays were carried out in triplicate 10µL samples on an ABI
7900HT Fast Real-Time PCR Sequence Detection System (Applied Biosystems).
Thermocycling conditions used for the assay were as followed: 48°C for 30 minutes (reverse
transcription), 95°C for 10 minutes (initial denaturation and Taq activation) followed by 40
cycles at 95°C for 15 seconds (denaturation) and 60°C for 1 minute (annealing and extension).
The threshold was set within the linear phase of target gene amplification to calculate the cycle
number (CT value) at which the transcript was detected.
Gene expression values were calculated according to comparative ΔΔC T method as
described in Applied Biosystems User Bulletin #2 [60]. For each target gene primers/probe set,
validation experiments were previously conducted to demonstrate the efficiencies of target and
reference gene amplification were approximately equal [44]. Target genes were normalized to
the reference gene, 18s, and fold differences were calculated for each treatment group with
respect to normalized CT values for the negative control utilizing a calibrator at each time point.

Table 3-1: Target gene primer sequences [44, 61, 62]
Gene

GenBank #

hRunx2

NM 004348

hAlp

XM 001826

18s

?

Forward Primer

Reverse Primer

Taqman Probe

AACCCACGAAT
GCACTATCCA
CCGTGGCAACT
CTATCTTTGG

CGGACATACCAG
GGACATG
GCCATACAGGAT
GGCAGTGA

CCTTTACTTACACCCC
GCCAGTCACCTC
CATGCTGAGTGACAC
AGACAAGAAGCCC

Proprietary of ABI

Proprietary of ABI

Proprietary of ABI

Reporter/
Quencher
FAM/
TAMRA
FAM/
TAMRA
JOE/
TAMRA
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3.2.4 Statistical analysis

For all real-time RT-PCR assays, statistics were performed using the GraphPad Prism
Program version 4.0b (San Diego, CA). The coefficient of variation was calculated from three
assay replicates and did not exceed 3% for all treatment groups [44]. A two-way ANOVA and
Bonferroni post hoc test was used for each experiment. If statistical significance was determined
using a two-way ANOVA, further analysis using a one-way ANOVA followed by a Bonferroni
post hoc test was completed. A p-value of ≤0.05 was considered significant. All experiments
were repeated at least two times and one representative experiment is shown.
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3.3 Results and Discussion

3.3.1 PAPP-A up-regulates Runx2 gene expression

It has been previously shown that PAPP-A directly up-regulates Runx2 gene expression
in hAMSC [44]. To confirm these results, I treated hAMSC with 200 ng/mL purified PAPP-A
protein. After 12 hours in culture, hAMSC that had been treated with PAPP-A exhibited a 200fold increase in Runx2 gene expression when compared to the negative control, mesenchymal
stem cell growth medium (MSCGM). After 12 hours, Runx2 gene expression began to decrease
towards basal levels (Figure 3-1A). There was a statistically significant increase in Runx2 gene
expression at 24 hours in the positive control (Os+) when compared to the negative control
(MSCGM) and PAPP-A treated cells. There was no statistical difference, however, between the
negative control and PAPP-A treated cells at 24 hours. Runx2 is an early marker of osteoblast
differentiation suggesting that at 24 hours, detection above basal levels may be too late.
The results obtained at 12 hours have been independently demonstrated twice under same
experimental conditions. Figure 3-1B depicts the results obtained in the other independent
experiment. In this experiment, cells treated with PAPP-A exhibited approximately a 400-fold
increase in Runx2 gene expression when compared to the negative control. At 24 hours of
treatment, there was no statistical difference between any of the groups.
Runx2 is the earliest known and most specific marker of osteoblast differentiation [10].
The role of Runx2 in bone formation has been demonstrated by numerous studies. A complete
Runx2 mouse knockout model resulted in a lack of ossification [63, 64]. Genetic mutations in
the Runx2 gene have been linked to skeletal abnormalities such as cleidocranial dysplasia [64].
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I, along with Jadlowiec et al [44], demonstrated that purified PAPP-A is capable of inducing
Runx2 gene expression in hAMSC without addition of an osteogenic supplement such as
dexamethasone. In this particular study, a 3.2-fold increase in Runx2 gene expression was
detected at 12 hours in cells treated with 200 ng/mL PAPP-A when compared to cells treated
with basal medium lacking PAPP-A [44]. While a similar trend in the increase of Runx2
expression in cells treated with PAPP-A at 12 hours was detected in both studies, the results of
my study showed a higher level of Runx2 gene expression. Experimental set up was similar
between the two studies with the exception of three variables: the lot number of the cells used,
the passage number of the cells used and the level of confluence in tissue culture plastics.
hAMSC exhibit different characteristics after a certain passage number and have the potential to
exhibit different characteristics based on the sex, age and race of the donor. It is not known
whether the cells used for the two studies were of an early or late passage number or if the sex,
age and race of the donor were of similar origin. In addition, the cells used for Jadlowiec et al
[44] were at a 70% level of confluence and the cells used in my study were of a lower level of
confluence (approximately 30-40%). When hAMSC become more confluent, they become
contact inhibited and begin to differentiate on their own [21]. Different sets of genes are
expressed at different stages of differentiation. The cells used in the Jadlowiec et al [44] study
may have been at different levels of differentiation due to a higher degree of confluency, making
it possible that Runx2 gene expression levels varied among the cells. The cells used in my
experiments are more likely to be at similar stages of differentiation thus expressing a more
uniform range of Runx2 gene expression.
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Figure 3-1: Runx2 gene expression. hAMSC were cultured in
MSCGM (open bars), MSCGM with osteogenic supplement (black
bars) or 200 ng/mL purified PAPP-A in complete medium (gray
bars) and RNA extracted after 12 and 24 hours. Real-time RT-PCR
for Runx2 gene expression was performed. a, b and c represent
statistically significant values within respective time point, p≤0.05
as determined via one-way ANOVA and Bonferroni post hoc test;
mean ± SEM, n = 3.
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3.3.2 PAPP-A up-regulates Alkaline Phosphatase gene expression

To further illustrate the ability of PAPP-A to enhance expression of osteoblast marker
genes, I treated hAMSC with 200 ng/mL purified PAPP-A in the absence of an osteogenic
supplement and extracted RNA at 6 and 18 hours. At 18 hours, hAMSC treated with PAPP-A
exhibited a statistically significant 1.5 fold increase in alkaline phosphatase gene expression
when compared to the negative control, MSCGM (Figure 3-2:A). These results have been
demonstrated twice under same experimental conditions (Figure 3-2:B). In this experiment
(figure 3-2:B), cells treated with PAPP-A exhibited a significant 3 fold difference in alkaline
phosphatase gene expression when compared to the negative control. However, the positive
control appeared to have a higher of level of expression when compared to the negative control
even though it was not statistically significant. In two additional studies under the same
conditions, there was no significant increase in differentiation in response to PAPP-A at 18 hours
(Figure 3-3, representative image shown). In the same two studies, the positive control, Os+,
failed to work and demonstrated a significantly lower level of Runx2 expression when compared
to the negative control, MSCGM.
In this study, I was able to demonstrate that alkaline phosphatase expression is enhanced
when treated with PAPP-A, in the absence of an osteogenic supplement. It has been previously
shown that alkaline phosphatase expression is enhanced in hAMSC when treated with
dexamethasone, ascorbic acid and β-glycerophosphate [65].

The increase in alkaline

phosphatase expression along with increased Runx2 expression suggests that PAPP-A may be a
key molecule in osteoblast differentiation.
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Figure 3-2: Alkaline phosphatase gene expression. hAMSC
were cultured in MSCGM (open bars), MSCGM with osteogenic
supplement (black bars) or 200 ng/mL purified PAPP-A in
complete medium (gray bars) and RNA extracted after 12 and 24
hours. Real-time RT-PCR for alkaline phosphatase gene
expression was performed. a, b and c represent statistically
significant values, p≤0.05 as determined via one-way ANOVA
and Bonferroni post hoc test; mean ± SEM, n = 3.
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Figure 3-3: Alkaline phosphatase gene expression. hAMSC
were cultured in MSCGM (open bars), MSCGM with osteogenic
supplement (black bars) or 200 ng/mL purified PAPP-A in
complete medium (gray bars) and RNA extracted after 12 and 24
hours. Real-time RT-PCR for alkaline phosphatase gene
expression was performed. a, b and c represent statistically
significant values, p≤0.05 as determined via one-way ANOVA
and Bonferroni post hoc test; mean ± SEM, n = 3.
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CHAPTER 4- CONCLUSIONS

I demonstrated that addition of purified PAPP-A did not enhance proliferation of
hAMSC. However, addition of purified PAPP-A did initiate changes in osteoblast gene
expression in hAMSC without addition of an osteogenic supplement such as dexamethasone.
Expression of Runx2, an early marker of osteoblast differentiation, was induced in hAMSC by
addition of purified PAPP-A to growth medium in two experiments, as previously shown by
Jadlowiec et al [44]. In addition, purified PAPP-A increased gene expression of alkaline
phosphatase in two independent experiments, another marker of osteoblast differentiation
occurring after initiation of Runx2 gene expression.
In an unbound form, PAPP-A cleaves certain binding proteins from Insulin-like growth
factor-I (IGF-I). This allows IGF-I to bind to its receptor on the cell surface, activating an
intercellular pathway involved in cellular proliferation. Therefore, addition of PAPP-A to
culture medium would potentially stimulate the cells to begin proliferating. On the contrary, this
phenomenon was not observed in the present studies. The PAPP-A used for these studies was a
commercially available protein, purified from ion-exchange chromatography, affinity
chromatography, gel-filtration and negative immunoaffinity chromatography. This PAPP-A is in
a heterotetrameric complex with its physiological inhibitor, proMBP. Since there are no known
mechanisms in vitro to free PAPP-A from its complex, the PAPP-A in these studies may have
been rendered inactive. If so, it would not be able to cleave IGFBP-4 from IGF-I and IGF-I
would not be able to bind to its receptor on the cell surface. Addition of purified PAPP-A did
not stimulate cellular proliferation through measurement with two different assays. This is to be
expected because complexed PAPP-A is incapable of its proteolytic activity.

43

It was hypothesized that the purified version of PAPP-A would also be incapable of
stimulating differentiation due to its lack of proteolytic activity. This was not the case in my
experiments. Despite the lack of proteolytic activity, purified PAPP-A significantly induced
expression of two markers of osteoblast differentiation, Runx2 and alkaline phosphatase. This
leads to three speculations: 1) PAPP-A has functions outside of its proteolytic activity, 2) the
heterotetrameric complex is required or aids in PAPP-A’s differentiative abilities or 3) PAPP-A
acts in a manner independent of IGF-I
Proliferation and differentiation studies were also conducted with recombinant forms of
PAPP-A. A wild type and protease deficient PAPP-A along with a mock transfected control
were also used. In reference to the proliferation studies, results showed variation from
experiment to experiment (figures S-4 through S-11, pages 57-70). There was no obvious
indication that there was an increase in proliferation due to addition of recombinant PAPP-A. In
addition, mock transfected control without any PAPP-A exhibited a dose-dependent response in
the cells. An explanation for this involves the production of these recombinant PAPP-As and
mock transfected controls. These proteins were cultured in medium containing serum. When
harvested, a small amount of serum was retained in the protein solution. This small amount of
serum may have had the potential to cause the dose-dependent responses in the mock transfected
control samples and possibly cause the variation observed among the experiments in which the
recombinant forms were used. The proteolytic activity of PAPP-A may be necessary to induce
proliferation in cells, thus explaining why the protease-deficient PAPP-A did not significantly
increase proliferation.
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Appendix A: Supplemental Protocols

5.1 Cell culture
A serum starvation experiment using MG-63 was set up to determine the appropriate
period of time to arrest the cells at G0 without compromising the viability of the cells. To do
this, cells were seeded in complete serum for 24 hours to allow the cells to attach either to plastic
tissue culture ware or to plastic cover slips. After the initial 24-hour attachment period, the
medium was aspirated and the cells were washed two times with serum free medium. Serum
free medium, 1% FBS medium and 10% FBS medium were added to separate wells. The cells
were cultured in this manner for a period of 24, 48, 72 and 96 hours. After the experimental
starvation period, the Live/Dead viability/cytotoxicity and CyQUANT cell proliferation assays
were performed to determine the optimal starvation period. Additional experimental treatments
periodically used include varying concentrations of PAPP-A (400 ng/mL, 200 ng/mL, 100
ng/mL and 50 ng/mL), the use of recombinant forms of PAPP-A (wild-type, protease deficient
and a mock transfected control) [45], addition of PAPP-A to medium containing serum and
BMP-2 treatment (100 ng/mL).

5.2 LIVE/DEAD® Viability/Cytotoxicity Assay
The Live/dead viability/cytotoxicity assay employs the use of two fluorescent probes
capable of recognizing cell viability. The intracellular esterase activity of live cells converts the
non-fluorescent calcein AM into an intense fluorescent calcein, producing a green fluorescence.
In dead cells, the EthD-1 enters through the damaged cell membrane and binds to nucleic acids,
undergoing an intense fluorescent enhancement. The LIVE/DEAD® Viability/Cytotoxicity
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assay was initially used to observe proliferation and morphology of MG-63 cells upon incubation
with PAPP-A. Once normal morphology was established, CyQUANT and BrdU incorporation
replaced this method to obtain quantitative results. The procedure was performed according to
the manufacturer’s specifications. (Data not shown.)

5.3 Cellular Proliferation
5.3.1 CyQUANT
The CyQUANT Cell Proliferation Assay Kit (C-7026, Molecular Probes, Carlsbad, CA)
provides a rapid method of cellular proliferation detection without having to rely on cellular
metabolic activity. The principle behind CyQUANT relies on a green fluorescent dye,
CyQUANT GR dye, which binds to nucleic acids resulting in a strong fluorescent enhancement.
Cells are subjected to one freezing cycle consisting of 24 hours and a brief thawing cycle prior to
cell lysis. Cells are lysed by addition of a buffer that contains the CyQUANT GR dye. Reagent
preparation can be followed according to manufacturer’s specifications.

Fluorescence is

measured using a microplate reader with the excitation at 485 +/- 10 nm and emission being
detected at 530 +/- 12.5 nm. Analysis of plate results involves subtracting the blanks from each
sample and reporting cellular proliferation as units of fluorescence, an arbitrary number.
Experiments on MG-63 cells using the CyQUANT assay consisted of seeding cells in
complete medium for 24 hours, washing the cells two times with serum free medium after the
initial 24 hour period followed by addition of serum free medium for 48 hours to arrest the cells
at G0. Following the 48-hour starvation period, the serum free medium was removed and
experimental medium was added. The MG-63 cells were then cultured in experimental medium
for 48 hours followed by preparation for CyQUANT analysis. Analysis took place using an HTS
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7000 BioAssay Reader (Perkin Elmer, Wellesley, MA). Controls included a 10% serum control
(no starvation), an add-back control (starved followed by addition of 10% serum) and a serum
free control.
Experiments with the hAMSC were performed in a similar manner with the exception
that the starving period only lasted 18 hours instead of 48 hours. Previous studies have shown
that the survival rate of hAMSC begins to decrease after 18 hours without serum [44]. Controls
are the same as listed in the above paragraph.

5.3.2 BrdU Incorporation
The BrdU Incorporation assay is a more sensitive method to detect proliferating cell
numbers. 5’-bromo-2’-deoxyuridine (BrdU) is a non-radioactive pyrimidine analog of thymidine
thus making BrdU an attractive alternative due to safety and disposal reasons. BrdU functions
by becoming incorporated into the DNA of proliferating cells undergoing the S phase of the cell
cycle. After BrdU is incorporated into the DNA, a monoclonal antibody for BrdU is used to
detect the amount incorporated.

A series of washes are performed according to the

manufacturer’s specifications. 25 µL of 1M H2SO4 was used to stop the colorimetric reaction by
mixing and reading the plate within 5 minutes after adding the stop solution. The absorbance
was read at 450 nm. The Cell Proliferation ELISA, BrdU (colorimetric) kit was purchased from
Roche Applied Science (Indianapolis, IN).
Experiments were set up in a similar manner to CyQUANT. Cells were seeded in
complete serum for 24 hours, starved for 48 hours (MG-63) or 18 hours (hAMSC) and cultured
with experimental medium and BrdU for 24-72 hours prior to assessment on a BIO-RAD Model
3550 Microplate Reader (GMI, Inc., Ramsey, MN). Controls included a 10% serum control (no
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starvation), an add-back control (starved followed by addition of 10% serum) and a serum free
control. In addition, three addition controls were used to ensure proper assay function. A blank
consisting of 100 µL of culture medium (one with 10% serum and one with 0% serum), 10 µL
BrdU and 100 µL of anti-BrdU-POD. These blanks supply information pertaining to the
unspecific binding of BrdU and anti-BrdU-POD conjugate to the tissue culture plate. The other
control is considered a background control. It consists of cells and 100 µL anti-BrdU-POD. It
provides information about the unspecific binding of the anti-BrdU-POD conjugate to cells in the
absence of BrdU. Both sets of controls were performed each time an assay was conducted.

5.4 RNA extraction
One step RT-PCR was used to analyze gene expression in hAMSC and MG-63 cells.
Cells were cultured in complete medium in a 6-well plate for 24 hours after which the medium
was removed and experimental medium was added. Experimental medium included addition of
200 ng/mL PAPP-A (commercial), 200 ng/mL PAPP-A (wild-type or protease deficient) or 100
ng/mL BMP-2 to complete growth serum. Positive and negative controls were used in every
case. The positive control consisted of 100 nM dexamethasone, 10 mM β-glycerophosphate and
0.05 mM ascorbic acid-2-phosphate added to complete growth medium. The negative control
consisted of complete growth medium with no additives. The cells were then cultured for
various time points (6, 12, 18, 24, 48 or 96 hours) and prepared for RNA extraction. At the
desired time point, cells were harvested by first aspirating the media, washing the cells with 1
mL PBS, aspiration of the PBS and followed by detachment with 200 µL of Trypsin/EDTA. The
Trypsin/EDTA was neutralized with 1 mL of complete growth medium. The cell solution was
then collected and placed in an RNase-free microcentrifuge tube. The tubes were centrifuged for
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five minutes at 10,000 – 12,000 rpm. The supernatant was aspirated and the cell pellet was flash
frozen by submerging the microcentrifuge tube in liquid nitrogen for approximately two minutes.
The samples were immediately stored at -80°C until time for RNA extraction.

RNA extraction procedure: (adapted from the RNeasy Mini Handbook)
*All centrifugations occur at 10,000 – 12,000 rpm.

1) Disrupt samples by mixing 350 µL of buffer RLT and β-mercaptoethanol.
2) Homogenize the sample by pipetting the lysate directly onto the QIAshredder spin
column in a 2 mL collection tube and centrifuging for two minutes.
3) Add 350 µL 70% ethanol to the homogenized lysate and mix well.
4) Transfer up to 700 µL of the sample, including any precipitate to an RNeasy mini column
in a 2 mL collection tube. Close the tube gently and centrifuge for 15 seconds. Discard
the flow-through.
5) Pipette 350 µL buffer RW1 onto the RNeasy mini column and centrifuge for 15 seconds.
Discard the flow-through.
6) To allow for DNase digestion, pipette 80 µL DNase I incubation mix directly onto the
RNeasy silica-gel membrane. (DNase I incubation mix is prepared by adding 10 µL
DNase stock solution to 70 µL buffer RDD. Invert the tube gently to mix the solution.)
Place column with 2 mL collection tube on the bench-top for 15 minutes at room
temperature (20-30°C).
7) Pipette 350 µL buffer RW1 onto the RNeasy mini column in the 2 mL collection tube
and centrifuge for 15 seconds. Discard the flow-through.
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8) Transfer the RNeasy mini column into a new 2 mL collection tube. Pipette 500 µL buffer
RPE onto the RNeasy mini column. Close the tube gently and centrifuge for 15 seconds.
Discard the flow-through.
9) Add another 500 µL buffer RPE to the RNeasy mini column. Close the tube gently and
centrifuge for 2 minutes to dry the RNeasy silica-gel membrane. Discard the flowthrough.
10) Centrifuge RNeasy mini column in 2 mL collection tube for one minute to eliminate any
chance of buffer RPE carryover.
11) To elute the RNA, transfer the RNeasy mini column to a new 1.5 mL collection tube.
Add 30 µL RNase-free water directly onto the RNeasy silica-gel membrane. Close the
tube gently and centrifuge for one minute.
12) Store sample at -80°C until ready for analysis.

5.5 Real-time RT-PCR analysis
Real-time RT-PCR was performed using TaqMan® One-Step PCR Master Mix Reagents
Kit purchased from Applied Biosystems (Long Beach, CA). The procedure was set up to run 10
µL samples in a 384 optically clear well plate. To achieve this, the master mix, reagents,
primers, probes and RNA samples were thawed and maintained on ice. One master mix solution
was made for each target gene (see adapted protocol below). 18s ribosomal primers and probes
were used as the reference housekeeping gene and were designed and purchased from Applied
Biosystems (Long Beach, CA). Target gene primers and probes were purchased from Integrated
DNA technologies (Coralville, IA). Sequences for target gene primers and probes along with
reporter and quencher dyes are shown in table S-1. Real-time RT-PCR assays were carried out
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in triplicate, run on a 7900 HT Fast Real-Time PCR System and analyzed by SDS 2.2 software
(Applied Biosystems). Thermocylcing conditions used for the assay: 48°C for 30 minutes
(reverse transcription), 95°C for 10 minutes (initial denaturation), followed by 40 cycles at 95°C
for 15 seconds (denaturation) and 60°C for 45 seconds (annealing and extension). The threshold
was set within the linear phase of target gene amplification to calculate the cycle number (CT
value) at which the transcript was detected.
Gene expression values were calculated according to comparative ΔΔC T method as
described in Applied Biosystems User Bulletin #2 [60]. For each target gene primers/probe set,
validation experiments were previously conducted to demonstrate the efficiencies of target and
reference gene amplification were approximately equal [44]. Target genes were normalized to
the reference gene, 18s, and fold differences were calculated for each treatment group with
respect to normalized CT values for the negative control utilizing a calibrator at each time point.

Real-time RT-PCR sample preparation (Acknowledgements: Julie Jadlowiec, Bone Tissue
Engineering Center, Carnegie Mellon University)
1) Prepare a separate master mix for each gene being analyzed.
2) Calculate the volumes for each reagent. (See Calculation for Master Mix below.)
3) Prepare master mix on ice for each gene in manner noted below. Mix reagents
thoroughly before adding to master mix.
4) Once all components have been added, thoroughly vortex master mix.
5) Aliquot 39 µL of master mix to RNase-free microcentrifuge tubes (one for each sample
be analyzed).
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6) Vortex RNA sample and add 1 µL of RNA to each sample tube containing appropriate
master mix.
7) Vortex samples and aliquot 10 µL of each sample in triplicate to an optically clear 384
well plate.
8) Upon completion, cover plate with optical adhesive cover.
9) Plates were analyzed on the ABI 7900HT at the University of Pittsburgh Genomics and
Proteomics Core Facility.
Calculation for Master Mix:
Volume
Component
(per reaction, in µL)
Taqman One-Step Master Mix (2X) 5
RNase free H2O
3.95
Forward Primer
0.2
Reverse Primer
0.2
Probe
0.2
RT/RNase Inhibitor (40X)
0.25
Total
9.8

Volume (µL)
for n=12 reactions
288
227.52
11.52
11.52
11.52
14.4
564.48

Forward/Reverse Primer concentrations:
Target Genes: 10 µM
18S: 2.5 µM
Probe concentration:
Target Genes: 5 µM
18S: 5 µM
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5.6 Agarose Gel
An agarose gel was run with RT-PCR samples containing 18s and alkaline phosphatase
primers (Figure S-14). One gram of agarose was mixed with 50 mL TAE buffer 1X and heated.
Five µL of ethidium bromide was added to the agarose/TAE solution and swirled gently. The
liquid gel was poured into an appropriate cast and allowed to set for 35 minutes. Samples were
prepared on ice by adding the following to each tube: 2µL loading dye and 10 µL sample. The
samples were vortexed and heated for 10 minutes. Samples were then loaded into the wells. The
gel was covered with TAE 1X running buffer and voltage was set between 66-70 volts. After
approximately one to one and a half hours later, a UV light was used to examine the band
location (Figure S-14).

5.7 Statistical analysis
For all real-time RT-PCR assays, statistics were performed using the GraphPad Prism
Program version 4.0b (San Diego, CA). The coefficient of variation was calculated from three
assay replicates and did not exceed 3% for all treatment groups [44]. A two-way ANOVA and
Bonferroni post hoc test was used in addition to an occasional one-way ANOVA when needed.
A p-value of ≤0.05 was considered significant.
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Appendix on Additional Studies
The following figures include experiments that provided background information for the
previous chapters or did not contain enough replicates to provide valid information.

MG-63 Serum Starvation

a. Rationale
To determine whether PAPP-A without help from FBS was having an effect on the
proliferation of MG-63 cells, it was necessary to arrest the cells at G0 in the cell cycle. To do
this, several experiments were conducted to determine an effective time period to sufficiently
starve the cells without compromising the viability of the cells.

b. Materials and Methods
MG-63 cells were seeded in complete serum for 24 hours to allow the cells to attach to
plastic tissue culture ware. After the initial 24-hour attachment period, the medium was
aspirated and the cells were washed two times with serum free medium. Serum free medium,
1% FBS medium and 10% FBS medium were added to separate wells and were cultured in this
manner for a period of 48 or 120 hours. Following the starvation period, the CyQUANT cell
proliferation assay was performed to determine the optimal starvation period.

c. Statistical Analysis
All data is reported as mean ± SEM, n=3 or greater, tested with a one-way ANOVA
followed by a Bonferroni post hoc test with p≤0.05.
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d. Results and Discussion
At 48 and 120 hours, serum containing 10% FBS has a statistically higher level of
fluorescence per mm^2 when compared to 1% and 0% FBS (Figures S-1 and S-2). There was no
significance between 1% FBS and 0%FBS at 120 hours, however, at 48 hours there was a
significant difference between the two treatments.

This suggests that at 48 hours, the

proliferative abilities of the cells had slowed. At 120 hours, cells numbers appeared to be
drastically reduced under phase contrast microscopy (data not shown). A starvation period of 48
hours was used for future experiments.
A preliminary study including commercially purified PAPP-A was included. Cells were
starved for 48 hours followed by treatment with four concentrations of PAPP-A in either 1% or
0% FBS. There was a significant difference between 400 and 50 ng/mL PAPP-A in 1% FBS and
between 400 and 100 ng/mL and 100 and 50 ng/mL PAPP-A in 0% FBS (figure S-3 B). Two
separate time points were measured for the controls to ensure the cells were being starved. There
were statistical differences between each control for each time point (figure S-3 A).
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Figure S-1: MG-63 serum starvation of 120 hours.
Results were analyzed via CyQUANT and are represented
2
as units of fluorescence per mm . Different letters
represents statistical significance. n=4; p≤0.001 as
determined via one-way ANOVA and Bonferroni post hoc
test; FBS = Fetal Bovine Serum.
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Figure S-2: MG-63 serum starvation of 48 and 120 hours.
Results were analyzed via CyQUANT and are represented as
2
units of fluorescence per mm . Different letters represents
statistical significance. n = 3; p≤0.01 as determined via one-way
ANOVA and Bonferroni post hoc test; FBS = Fetal Bovine
Serum.
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Figure S-3: MG-63 serum starvation and preliminary PAPP-A results. MG63 cells were seeded in 10% FBS for 24 hours. After initial 24 hour period, cells
were starved for 48 hours (refer to day 0) with the exception of the 10% FBS
control. Following the starvation period, 10%, 1% or 0% FBS was added to the
wells for 48 hours (refer to day 2). A) Controls and B) Commercially available
PAPP-A. Black bars represent 10% FBS, white bars represent 1% FBS and gray
bars represent 0% FBS (A). Results were analyzed via CyQUANT and are
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represented as units of fluorescence per mm . A) Letters and B) * represent
statistical significance. p≤0.05 as determined via one-way ANOVA and
Bonferroni post hoc test unless otherwise noted. n = 3; mean ± SEM.
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Additional studies and figures on MG-63 cell proliferation

a. Rationale
To determine if proteolytic activity is necessary for PAPP-A to function, two
recombinant versions were used: wild-type and protease deficient. The wild-type PAPP-A is
supposed to be in an unbound form while the protease deficient PAPP-A lacks its ability to
proteolytically cleave [45].

b. Materials and Methods
MG-63 cells were seeded in complete serum for 24 hours to allow the cells to attach to
tissue culture platistics. After the initial 24-hour attachment period, the medium was aspirated
and the cells were washed two times with serum free medium. The cells were starved with
serum free medium for 48 hours. Following this 48 hour time period, experimental medium was
added to separate wells and cultured for a period of 24, 48 or 96 hours. The CyQUANT cell
proliferation or BrdU incorporation assays were performed to determine the effect of PAPP-A on
cellular proliferation. Four concentrations of wild-type, protease deficient or commercially
available PAPP-A were used: 400 ng/mL, 200 ng/mL, 100 ng/ml or 50 ng/mL in media
containing 0% or 1% FBS.

c. Statistical Analysis
All data is reported as mean ± SEM, n=3 or greater, tested with a one-way ANOVA
followed by a Bonferroni post hoc test with p≤0.05.
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d. Results and Discussion
Initially, two of the four concentrations used in chapter 2 were selected for preliminary
experiments. MG-63 cells were treated with 400 ng/mL or 100 ng/mL PAPP-A in 0% FBS for
24 hours and analyzed via BrdU incorporation. In the first experiment, figure S-4 A, only the
cells treated with 100 ng/mL protease deficient PAPP-A showed a significant decrease in
proliferation when compared to the addback control. In an attempt to repeat the experiment,
only the positive control 10% FBS control shows statistical significance when compared to the
addback control (figure S-4 B).
As discussed in chapter 2, purified PAPP-A did not induce proliferation in MG-63 cells
at 24 hours. Similar results were found in figure S-4. The doubling time of MG-63 cells is
approximately 36 hours, suggesting that a treatment time of 24 hours might not be sufficient
enough to detect a change in proliferation. To rectify this, a treatment time of 48 hours was
used. In these studies, only the recombinant forms of PAPP-A were used at concentrations of
400 and 100 ng/mL. In addition, PAPP-A was added to 0% FBS and 1% FBS. In figure S-5
B–D, there was a statistically significant decrease in proliferation in groups treated with PAPP-A
in 0% FBS as determined via CyQUANT. There was no statistical significance between groups
treated with PAPP-A in 1% FBS and the addback control. The experiment was repeated, and
different results were obtained. In figure S-6 B, 400 ng/mL and 100 ng/mL wild-type PAPP-A
in 1% FBS exhibited a statistically significant increase in proliferation when compared to the
addback control. Cells treated with 100 ng/mL wild-type PAPP-A in 0% FBS showed a
significant decrease in proliferation when compared to the addback control. There was no
statistical significance between groups treated with the protease deficient PAPP-A. In addition,
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cells treated with a mock transfected control showed significance among all treatment groups
when compared to the addback control.
A third experiment using the same PAPP-A concentrations but only in 0% FBS was
conducted. At 48 hours, cells treated with recombinant PAPP-A at both concentrations showed a
significant decrease in cellular proliferation when compared to the addback control as
determined via CyQUANT (figure S-7). These results resemble the trends seen in figure 2-5.
In figure S-8, cells were cultured for 96 hours in experimental medium instead of 48
hours like the previous experiments. Four concentrations of recombinant PAPP-A were used.
Wild-type PAPP-A at concentrations of 200 ng/mL, 100 ng/mL and 50 ng/mL showed a
significant decrease in proliferation as compared to the addback control. In addition, protease
deficient PAPP-A at concentrations of 100 ng/mL and 50 ng/mL showed a significant decrease
in proliferation when compared to the addback control.
The variation among results in the experiments using recombinant PAPP-A may be due
to the isolation method of the proteins. The proteins were extracted from cells that were grown
in medium containing serum. While the amount of serum may be negligible, it may be sufficient
to throw off the results. In most cases it appears as if addition of PAPP-A decreased levels of
proliferation, however, the results of these studies do not clearly exhibit a statistically significant
increase or decrease in proliferation in response to PAPP-A.
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Figure S-4: Effect of recombinant PAPP-A on MG-63 cell proliferation. A) MG-63
cells were treated with 400 or 100 ng/mL WT or PD in 0% FBS for 24 hours. B) MG-63
cells were treated with 400 or 100 ng/mL WT, PD or CP in 0% FBS for 24 hours. BrdU
incorporation was used to determine proliferative response. Results are shown as % BrdU
incorporation. n = 4; mean ± SEM. Results are normalized to addback control. *
represents statistical significance from addback control. p≤0.05 as determined via oneway ANOVA and Bonferonni post hoc test. FBS = Fetal Bovine Serum; Addback =
starvation for 18 hours with 0% FBS, followed by addition of 10% FBS for 24 hours; WT
= recombinant wild-type PAPP-A; PD = recombinant protease-deficient PAPP-A; MT =
mock transfected control; CP = Commerical PAPP-A. FBS = Fetal Bovine Serum
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Figure S-5: Effect of recombinant PAPP-A on MG-63 cell proliferation. MG-63
cells were seeded in 10% FBS for 24 hours. After initial 24 hour period, cells were
starved for 48 hours. Following the starvation period, recombinant PAPP-A in 1% or
0% FBS was added to the wells for 48 hours. A) controls, B) wild-type PAPP-A, C)
protease deficient PAPP-A and D) Mock Transfected Control. Results were analyzed
2
via CyQUANT and are represented as units of fluorescence per mm . * represents
statistical significance as compared to the addback control. p≤0.05 as determined via
one-way ANOVA and Bonferonni post hoc test. n = 3; mean ± SEM. FBS = Fetal
Bovine Serum
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Figure S-6: Effect of recombinant PAPP-A on MG-63 cell proliferation. MG-63 cells
were seeded in 10% FBS for 24 hours. After initial 24 hour period, cells were starved for
48 hours. Following the starvation period, recombinant PAPP-A in 1% or 0% FBS was
added to the wells for 48 hours. A) controls, B) wild-type PAPP-A, C) protease deficient
PAPP-A and D) Mock Transfected Control. Results were analyzed via CyQUANT and are
2
represented as units of fluorescence per mm . * represents statistical significance as
compared to the addback control. p≤0.05 as determined via one-way ANOVA and
Bonferroni post hoc test. n = 3; mean ± SEM. FBS = Fetal Bovine Serum.
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Figure S-7: Effect of recombinant PAPP-A on MG-63 cell proliferation. MG-63
cells were seeded in 10% FBS for 24 hours. After initial 24 hour period, cells were
starved for 48 hours. Following the starvation period, recombinant PAPP-A in 0%
FBS was added to the wells for 48 hours. A) controls, B) wild-type PAPP-A, C)
protease deficient PAPP-A and D) Mock Transfected Control. Results were
2
analyzed via CyQUANT and are represented as units of fluorescence per mm . *
represents statistical significance as compared to the addback control. p≤0.05 as
determined via one-way ANOVA and Bonferonni post hoc test. n = 4; mean ±
SEM. FBS = Fetal Bovine Serum.
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Figure S-8: Effect of recombinant PAPP-A on MG-63 cell proliferation. MG-63 cells
were seeded in 10% FBS for 24 hours. After initial 24 hour period, cells were starved for
48 hours. Following the starvation period, recombinant PAPP-A in 0% FBS was added to
the wells for 96 hours. A) controls, B) wild-type PAPP-A, C) protease deficient PAPP-A
and D) Mock Transfected Control. Results were analyzed via CyQUANT and are
2
represented as units of fluorescence per mm . * represents statistical significance as
compared to the addback control. p≤0.05 as determined via one-way ANOVA and
Bonferonni post hoc test. n = 4; mean ± SEM. FBS = Fetal Bovine Serum.
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Additional hAMSC proliferation studies and figures

a. Rationale
To determine if proteolytic activity is necessary for PAPP-A to function, two
recombinant versions were used: wild-type and protease deficient. The wild-type PAPP-A is
supposed to be in an unbound form while the protease deficient PAPP-A lacks its ability to
proteolytically cleave [45].

b. Materials and Methods
hAMSC were seeded in complete serum (MSCGM) for 24 hours to allow the cells to
attach to tissue culture plastics. After the initial 24-hour attachment period, the medium was
aspirated and the cells were washed two times with serum free medium. The cells were starved
with serum free medium for 18 hours. Following this 18 hour time period, experimental medium
was added to separate wells and cultured for a period of 24 or 72 hours. BrdU incorporation
assays were performed to determine the effect of PAPP-A on cellular proliferation. Four
concentrations of wild-type, protease deficient or commercially available PAPP-A were used:
400 ng/mL, 200 ng/mL or 100 ng/mL serum free medium (BM), complete serum (MSCGM) or
50% serum (MSCGM/BM)

c. Statistical Analysis
All data is reported as mean ± SEM, n=3 or greater, tested with a one-way ANOVA
followed by a Bonferroni post hoc test with p≤0.05.
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d. Results and Discussion
hAMSC were treated with recombinant PAPP-A in serum free medium for 24 hours. All
experimental groups appeared to show a significant increase in proliferation over the addback
control (figure S-9 A). However, the addback control exhibited basal levels of proliferation
suggesting that this control did not work. The positive and negative controls appeared to work,
however without an appropriate addback control, the positive increase in treatment groups
should not be considered valid. In addition, hAMSC double every 2-3 days. At 24 hours, the
cells have not had time to complete a full cell cycle. Also, hAMSC are more sensitive than MG63 cells, which is why they only have a starvation period of 18 hours. It is possible that the cells
in the addback control wells did not survive the starvation period as well as the other cells did.
Figure S-9 B-D represent experiments with the same experimental set up with the
exception of a treatment of 72 hours instead of 24, and addition of commercially purified PAPPA. Results varied from experiment to experiment. Part B showed a decrease in proliferation
when cells were treated with 100 ng/mL commercial PAPP-A in comparison to the addback
control. The controls for this experiment also had high standard errors or the mean. Part C
showed a decrease in proliferation in all experimental groups when compared to the addback
control. Part D showed an increase in proliferation when cells were treated with 400 ng/mL
wild-type PAPP-A. The extended treatment period would have allowed the cells to finish at least
one population doubling, variation between experiments was still present.
To account for the possibility that the cells were not fully recovering from the starvation
period, recombinant and purified forms of PAPP-A were added to medium containing 0% serum
(BM), 50% serum (MSCGM/BM) or 100% serum (MSCGM). Only one concentration of PAPPA was used: 200 ng/mL. In figure S-10 B, all experimental groups exhibited a significant
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decrease in proliferation when compared to the addback control. The PAPP-A in these groups
was added to basal medium that did not contain any serum. In figure S-10 D, similar results
were present; PAPP-A was added to medium containing 50% serum. There were no differences
in proliferation in cells treated with PAPP-A in 100% serum (figure S-10 C). When the
experiment was repeated, similar results were obtained for cells treated with PAPP-A in 0%
serum (figure S-11 B). Cells treated with protease deficient PAPP-A in 100% serum, however,
showed a significant increase in proliferation when compared to the addback control (figure S-11
C). Definitive results cannot be concluded from these results due to variation.
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Project 2: hAMSC, BrdU, and PAPP-A
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Figure S-9: Effect of recombinant PAPP-A on proliferation of hAMSC. hAMSC were
treated with 400 and 100 ng/mL WT, PD and purified PAPP-A in basal medium for 24 (A) or
72 hours (B-D). BrdU Incorporation was used to determine proliferative response. Results are
shown as % BrdU incorporation. Mean ± SEM. A - C : n = 4, D: n = 6. (*) represents
statistically significant from addback control, p≤0.05. MSCGM = Mesenchymal Stem Cell
Growth Medium; BM = Basal Medium, Addback = starvation for 18 hours with BM; followed
by addition of MSCGM for 24 (A) or 72 hours (B-D); WT = recombinant wild-type PAPP-A;
PD = recombinant protease deficient PAPP-A; MT = mock transfected control and CP =
purified PAPP-A.
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Figure S-10: Effect of PAPP-A on proliferation of hAMSC. hAMSC were treated with 200
ng/mL WT, PD and purified PAPP-A in B) BM, C) MSCGM, or D) MSCGM/BM (1:1 vol) for 72
hours. A) represents controls. BrdU incorporation was used to determine proliferative response.
Results are shown as % BrdU incorporation. n = 4; mean ± SEM. Results are normalized to addback
control. (*) represents statistical significance as compared to addback control. p≤0.05 as determined
via one-way ANOVA and Bonferroni post hoc test. MSCGM = Mesenchymal Stem Cell Growth
Medium; BM = Basal Medium; Addback = starvation for 18 hours with BM, followed by addition of
MSCGM for 72 hours; CP = purified PAPP-A; WT = recombinant wild-type PAPP-A; P D =
recombinant protease-deficient PAPP-A; MT = mock transfected control
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Figure S-11: Effect of PAPP-A on proliferation of hAMSC. hAMSC were treated with 200 ng/mL
WT, PD and purified PAPP-A in B) BM, C) MSCGM, or D) MSCGM/BM (1:1 vol) for 72 hours. A)
represents controls. BrdU incorporation was used to determine proliferative response. Results are
shown as % BrdU incorporation. n = 4; mean ± SEM. Results are normalized to addback control. *
represents statistical significance (A, B and D); * represents statistical significance from addback
control in C. p≤0.05 as determined via one-way ANOVA and Bonferroni post hoc test. MSCGM =
Mesenchymal Stem Cell Growth Medium; BM = Basal Medium; Addback = starvation for 18 hours
with BM, followed by addition of MSCGM for 72 hours; BM50:50 = starvation for 18 hours with
BM, followed by addition of MSCGM/BM (1:1 vol) for 72 hours; CP = purified PAPP-A; WT =
recombinant wild-type PAPP-A; PD = recombinant protease-deficient PAPP-A; M T = mock
transfected control.
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Additional RT-PCR studies:
Runx2 Gene Expression
hAMSC were seeded in complete serum for 24 hours prior to treatment with 200 ng/mL
PAPP-A. RNA was extracted at 6, 18 and 24 hours. Runx2 expression was analyzed via RTPCR. Figure S-12 A depicts a representative image of four replicate experiments and part B
depicts a representative image of 3 replicates. No significance was observed between treatment

A

Mean Fold Over Control

groups and controls.

6 Hours

18 Hours

Mean Fold Over Control

B

MSCGM

Os+
24 Hours

PAPP-A

Figure S-12: Runx2 gene expression. hAMSC were cultured in MSCGM
(open bars), MSCGM with osteogenic supplement (black bars) or 200 ng/mL
purified PAPP-A in complete medium (gray bars) and RNA extracted after 6
(A), 18 (A) and 24 hours (B). Real-time RT-PCR for Runx2 gene expression
was performed. a, b and c represent statistically different values, p≤0.05; mean
± SEM, n = 3. MSCGM = Mesenchymal Stem Cell Growth Medium.
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Alkaline Phosphatase Gene Expression
hAMSC were seeded in complete serum for 24 hours prior to treatment with 200 ng/mL
PAPP-A. RNA was extracted at 24 hours. Alkaline phosphatase expression was analyzed via
RT-PCR. Figure S-13 depicts a representative image of four replicate experiments. No

Mean Fold Over Control

significance was observed between treatment groups and controls.

MSCGM

Os+

PAPP-A

24 Hours

Figure S-13. Alkaline phosphatase gene expression. hAMSC
were cultured in MSCGM (open bars), MSCGM with osteogenic
supplement (black bars) or 200 ng/mL purified PAPP-A in
complete medium (gray bars) and RNA extracted after 24 hours.
Real-time RT-PCR for Runx2 gene expression was performed. a,
b and c represent statistically significant values, p≤0.05; mean ±
SEM, n = 3. MSCGM = Mesenchymal Stem Cell Growth
Medium.
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Figure S-14 Agarose gel of real-time PCR products. Lane
1: DNA Ladder; Lanes 2-7: 18s primers, Lanes 8-10: Alkaline
phosphatase primers.
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Appendix C- Statistical Values for included thesis figures

Figure 2-1: Incubation of MG-63 cells with PAPP-A (page 27)
2-1:A

One-way ANOVA
Bonferroni post hoc test

F = 64.14
df = 3, 8
P<0.0001

2-2:B

One-way ANOVA
Bonferroni post hoc test

F = 133.2
df = 4, 10
P<0.0001

Figure 2-2: Incubation of hAMSC with PAPP-A (page 29)
2-2:A

One-way ANOVA
Bonferroni post hoc test

F = 1700
df = 3,6
P < 0.0001

2-2:B

One-way ANOVA
Bonferroni post hoc test

F = 46
df = 3,8
P < 0.0001

Figure 3-1: Runx2 gene expression (page 36)
3-1:A
Interaction
Treatment
Time

F value
34.02
34.36
86.05

df
2
2
1

P value
P<0.0001
P<0.0001
P<0.0001

12-24 hours
Two-way ANOVA
Bonferroni post hoc test

12 hours
One-way ANOVA
Bonferroni post hoc test

F = 27.44
df = 2,4
P = 0.0046
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24 hours
One-way ANOVA
Bonferroni post hoc test
3-1:B
Interaction
Treatment
Time

F = 17.52
df = 2,5
P = 0.0055
F value
70.46
70.63
223.9

df
2
2
1

P value
P<0.0001
P<0.0001
P<0.0001

12-24 hours
Two-way ANOVA
Bonferroni post hoc test

12 hours
One-way ANOVA
Bonferroni post hoc test

F = 70.55
df = 2,3
P = 0.0030

24 hours
One-way ANOVA
Bonferroni post hoc test

F = 1.065
df = 2,3
P = 0.4472

Figure 3-2: Alkaline phosphatase gene expression (page 38)
3-2:A
Interaction
Treatment
Time

F value
6.2
11
0.7

df
2
2
1

P value
P = 0.0280
P = 0.0070
P = 0.4318

6-18 hours
Two-way ANOVA
Bonferroni post hoc test

6 hours
One-way ANOVA
Bonferroni post hoc test

F = 3.5
df = 2,4
P = 0.1302

18 hours

F = 84
77

3-2:B

One-way ANOVA
Bonferroni post hoc test

df = 2,3
P = 0.0023

18 hours
One-way ANOVA
Bonferroni post hoc test

F = 48
df = 2,4
P = 0.0016

Figure 3-3: Alkaline phosphatase gene expression (page 39)

Interaction
Treatment
Time

F value
4.732
27.8
4.216

df
2
2
1

P value
P = 0.0501
P = 0.0005
P = 0.0791

6-18 hours
Two-way ANOVA
Bonferroni post hoc test
Figure S-1: MG-63 serum starvation of 120 hours (page 54)
F = 171.1
df = 2,9
P < 0.0001

One-way ANOVA
Bonferroni post hoc test
Figure S-2: MG-63 serum starvation of 48 and 120 hours (page 54)

Interaction
Treatment
Time

F value
29.34
67.77
2.49

df
2
2
1

P value
P < 0.0001
P < 0.0001
P = 0.0009

48-120 hours
Two-way ANOVA
Bonferroni post hoc test
Figure S-3: MG-63 serum starvation and preliminary PAPP-A results (page 55)
S-3:A
Interaction

F value
12.37

df
2

P value
P = 0.0003
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Treatment
Time

73.95
9.27

2
1

P < 0.0001
P = 0.0003

0-2 days
Two-way ANOVA
Bonferroni post hoc test
S-3:B

1% FBS
One-way ANOVA
Bonferroni post hoc test
0% FBS
One-way ANOVA
Bonferroni post hoc test

F = 5.521
df = 3,8
P = 0.0238
F = 8.913
df = 3,8
P = 0.0062

Figure S-4: Effect of recombinant PAPP-A on MG-63 cell proliferation (page 59)
S-4:A

One-way ANOVA
Bonferroni post hoc test

F = 38
df = 9,28
P < 0.0001

S-4:B

One-way ANOVA
Bonferroni post hoc test

F = 2.0
df = 11,30
P = 0.0684

Figure S-5: Effect of recombinant PAPP-A on MG-63 cell proliferation (page 60)
S-5:A

One-way ANOVA
Bonferroni post hoc test

F = 49.89
df = 4,10
P < 0.0001

S-5:B

One-way ANOVA
Bonferroni post hoc test

F = 81.04
df = 4,10
P < 0.0001

S-5:C

One-way ANOVA
Bonferroni post hoc test

F = 35.19
df = 4,10
P < 0.0001
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S-5:D

One-way ANOVA
Bonferroni post hoc test

F = 25.44
df = 4,10
P < 0.0001

Figure S-6: Effect of recombinant PAPP-A on MG-63 cell proliferation (page 61)
S-6:A

One-way ANOVA
Bonferroni post hoc test

F = 83.49
df = 3,8
P < 0.0001

S-6:B

One-way ANOVA
Bonferroni post hoc test

F = 29.07
df =4,10
P < 0.0001

S-6:C

One-way ANOVA
Bonferroni post hoc test

F = 0.8773
df = 4,10
P = 0.5109

S-6:D

One-way ANOVA
Bonferroni post hoc test

F = 66.52
df = 4,10
P < 0.0001

Figure S-7: Effect of recombinant PAPP-A on MG-63 cell proliferation (page 62)
S-7:A

One-way ANOVA
Bonferroni post hoc test

F = 55.97
df = 3,12
P < 0.0001

S-7:B

One-way ANOVA
Bonferroni post hoc test

F = 123.5
df = 2,9
P < 0.0001

S-7:C

One-way ANOVA
Bonferroni post hoc test

F = 127.7
df = 2,9
P < 0.0001

S-7:D

One-way ANOVA
Bonferroni post hoc test

F = 125.2
df = 2,9
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P < 0.0001
Figure S-8: Effect of recombinant PAPP-A on MG-63 cell proliferation (page 63)
S-8:A

One-way ANOVA
Bonferroni post hoc test

F = 8.629
df = 4,15
P = 0.0008

S-8:B

One-way ANOVA
Bonferroni post hoc test

F = 10.64
df = 4,15
P = 0.0003

S-8:C

One-way ANOVA
Bonferroni post hoc test

F = 4.131
df = 4,15
P = 0.0188

S-8:D

One-way ANOVA
Bonferroni post hoc test

F = 5.294
df = 4,15
P = 0.0073

Figure S-9: Effect of recombinant PAPP-A on proliferation of hAMSC (page 67)
S-9:A

One-way ANOVA
Bonferroni post hoc test

F = 31.98
df = 8,24
P < 0.0001

S-9:B

One-way ANOVA
Bonferroni post hoc test

F = 3.304
df = 10,33
P = 0.0046

S-9:C

One-way ANOVA
Bonferroni post hoc test

F = 19.58
df = 10,30
P < 0.0001

S-9:D

One-way ANOVA
Bonferroni post hoc test

F = 4.126
df = 10,55
P = 0.0003

Figure S-10: Effect of recombinant PAPP-A on proliferation of hAMSC (page 68)
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S-10:A

One-way ANOVA
Bonferroni post hoc test

F = 20.88
df = 2,9
P = 0.0004

S-10:B

One-way ANOVA
Bonferroni post hoc test

F = 33.14
df = 4,15
P < 0.0001

S-10:C

One-way ANOVA
Bonferroni post hoc test

F = 1.225
df = 4,15
P = 0.3417

S-10:D

One-way ANOVA
Bonferroni post hoc test

F = 18.60
df = 4,15
P < 0.0001

Figure S-11: Effect of recombinant PAPP-A on proliferation of hAMSC (page 69)
S-11:A

One-way ANOVA
Bonferroni post hoc test

F = 17.12
df = 3,12
P = 0.0001

S-11:B

One-way ANOVA
Bonferroni post hoc test

F = 17.82
df = 4,15
P < 0.0001

S-11:C

One-way ANOVA
Bonferroni post hoc test

F = 3.787
df = 4,15
P = 0.0254

S-11:D

One-way ANOVA
Bonferroni post hoc test

F = 3.326
df = 4,15
P = 0.0387

Figure S-12: Runx2 gene expression (page 70)
S-12:A
Interaction

F value
0.09591

df
2

P value
P = 0.9092
82

Treatment
Time

5.668
0.1893

2
1

P = 0.0185
P = 0.6712

6-18 hours
Two-way ANOVA
Bonferroni post hoc test

S-12:B
One-way ANOVA
Bonferroni post hoc test

F = 0.8415
df = 2,6
P = 0.4763

Figure S-13: Alkaline phosphatase gene expression (page 71)
One-way ANOVA
Bonferroni post hoc test

F = 3.426
df = 2,6
P = 0.1018
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